Corylin

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Natural Science Foundation of China and 1 more

Model organisms1

Outcomes

Lipofuscin

downin worms1

1 study

Corylin decreases lipofuscin in worms.
“Corylin treatment significantly extended lifespan, improved locomotor performance, and reduced lipofuscin accumulation.”
Model organismscorylin treatment
Corylin promotes longevity in Caenorhabditis elegans through DAF-16 and SKN-1 coordinated activation of autophagy-mitochondrial homeostasis axis
Journal of ethnopharmacology21 Feb 2026

Latest

1 in 12 months

Journal of Ethnopharmacology24 Feb

Corylin promotes longevity in Caenorhabditis elegans through DAF-16 and SKN-1 coordinated activation of autophagy-mitochondrial homeostasis axis

Experiments in wormsInterventions

Paper

Corylin

Outcomes

Latest

Corylin promotes longevity in Caenorhabditis elegans through DAF-16 and SKN-1 coordinated activation of autophagy-mitochondrial homeostasis axis

Related